European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Multiple myeloma (MM) incidence is increasing globally.
• Outcomes for triple-class-exposed relapsed/refractory MM (TCE RRMM) remain poor despite novel therapies.
• Recent innovations include CAR T-cell therapy, ADCs, and bispecific antibodies.

Purpose of the Study:

• To provide a comprehensive overview of teclistamab's clinical profile.
• To offer expert recommendations for the optimal use of teclistamab in TCE RRMM.
• To guide physicians in patient selection, therapy initiation, and adverse event management.

Main Methods:

• Review of clinical data and expert opinion on teclistamab.
• Focus on patient selection criteria, including special populations.
• Strategies for adverse event prevention, monitoring, and management.

Main Results:

• Teclistamab, a BCMA-targeted bispecific antibody, shows efficacy in TCE RRMM.
• It is recommended from the second relapse onwards in updated guidelines.
• Demonstrates deep and durable responses with an acceptable safety profile.

Conclusions:

• Teclistamab represents a significant advancement for TCE RRMM patients.
• Clear guidance is needed for its routine clinical application.
• Physician support is crucial for maximizing teclistamab's therapeutic potential and improving patient outcomes.